ECOR

$6.81

Post-MarketAs of Mar 17, 8:00 PM UTC

electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation (“nVNS”) technology platform in the United States, the United Kingdom, and internationally.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$6.81
Potential Upside
5%
Whystock Fair Value$7.15
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation (“nVNS”) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a pres...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$54.45M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.50
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-337.84%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.19

Recent News

Zacks
Mar 5, 2026

Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 4, 2026

OmniAb, Inc. (OABI) Reports Q4 Loss, Misses Revenue Estimates

OmniAb, Inc. (OABI) delivered earnings and revenue surprises of -33.33% and -5.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 4, 2026

electroCore, Inc. (ECOR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

electroCore (ECOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Feb 27, 2026

Amneal Pharmaceuticals (AMRX) Q4 Earnings Top Estimates

Amneal (AMRX) delivered earnings and revenue surprises of +18.85% and -0.19%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Dec 24, 2025

Analysts Expect Breakeven For electroCore, Inc. (NASDAQ:ECOR) Before Long

We feel now is a pretty good time to analyse electroCore, Inc.'s ( NASDAQ:ECOR ) business as it appears the company may...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.